CEP
MDGL icon

Chicago Equity Partners’s Madrigal Pharmaceuticals MDGL Stock Holding History

Chicago Equity Partners’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,155
Closed -$247K – 847
2018
Q3 		$247K Hold
1,155
– – 0.01% 759
2018
Q2 		$323K Buy
+1,155
New +$203K 0.01% 728

Other funds holding MDGL

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Chicago Equity Partners's MDGL Position: Q4 2018 in Review

Chicago Equity Partners sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2018, closing a stake of 1,155 shares — an estimated $247K sold.

Chicago Equity Partners first reported a position in MDGL in Q2 2018 and held it in 2 quarters. The position peaked at $323K in Q2 2018. 136 funds tracked by Wall St. Rank hold MDGL as of Q4 2018.

  • Chicago Equity Partners reported no remaining Madrigal Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Chicago Equity Partners sold 1,155 Madrigal Pharmaceuticals shares in Q4 2018, an estimated $247K.
  • Chicago Equity Partners first reported a position in Madrigal Pharmaceuticals in Q2 2018 and held it in 2 quarters.
  • Chicago Equity Partners's Madrigal Pharmaceuticals position peaked at $323K in Q2 2018.
  • 136 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2018.

Based on Chicago Equity Partners's 13F filing for Q4 2018, filed 5 Feb 2019.